OA21.05LB Partners support, disclosure and side effects: facilitators of high maternal PrEP adherence in Cape Town, South AfricaOral Abstract SessionImplementation science, including structural interventions, PrEP & VMMC
PE23.04 Pathogen reduction (PR) as an alternative to donor deferral to mitigate the risk of transfusion-transmitted HIVE-posterPolicy and advocacy
OA10.02 Pathways to global access for novel HIV prevention technologiesOral Abstract SessionPolicy and advocacy
PE25.03 Patterns of adherence among South African women in a phase III randomized controlled trial of a dapivirine vaginal ring for HIV-1 preventionE-posterProduct acceptability and adherence
OA21.04 Peer-distributed HIV self-test kits to increase demand for HIV prevention and care services in rural KwaZulu-Natal, South Africa: a three-armed cluster-randomised trial comparing social-networks versus direct deliveryOral Abstract SessionClinical trial results
PE01.21 Perceived severity of HIV infection in the biomedical era and its association with sexual risk behavior among HIV-negative men who have sex with menE-posterBehavioural and social science research
PE01.37 Perspectives on use of PrEP from Black and Latinx sexual and gender minority youthE-posterBehavioural and social science research
OA19.05LB Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissueOral Abstract SessionPharmacology/PK and PD studies
OA06.01 Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancyOral Abstract SessionContraception, pregnancy and HIV prevention (incl. PMTCT)
PE04.03LB Phase 1 evaluation of the safety, acceptability, and pharmacokinetic profile of an OB-002H gelE-posterClinical trial results
seek-warrow-warrow-eseek-e291 - 300 of 444 items